Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and
oxygen supply to the tumor cells through the decrease of the vascular network and the …

Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …

Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus
fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ …

Patterns of genomic evolution between primary and metastatic breast cancer have not been
studied in large numbers, despite patients with metastatic breast cancer having dismal …

The signaling component of the mammalian Fibroblast Growth Factor (FGF) family is
comprised of eighteen secreted proteins that interact with four signaling tyrosine kinase FGF …

Background The epithelial-mesenchymal transition (EMT) enables dissociation of tumour
cells from the primary tumour mass, invasion through the extracellular matrix, intravasation …